Parallax Volatility Advisers, L.P. Novavax Inc Transaction History

Parallax Volatility Advisers, L.P.

$53.5 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$3.89 - $20.97 $25,701 - $138,548	-6,607 Reduced 25.22%	19,588 $247,000
Q1 2024 May 15, 2024	SELL	$3.76 - $6.02 $323,420 - $517,816	-86,016 Reduced 76.66%	26,195 $125,000
Q4 2023 Feb 14, 2024	BUY	$4.8 - $7.67 $220,238 - $351,922	45,883 Added 69.18%	112,211 $538,000
Q3 2023 Nov 14, 2023	BUY	$6.81 - $9.74 $451,693 - $646,034	66,328 New	66,328 $480,000
Q2 2022 Aug 15, 2022	BUY	$36.28 - $75.29 $1.44 Million - $2.99 Million	39,758 Added 128.57%	70,681 $3.64 Million
Q1 2022 May 16, 2022	SELL	$69.73 - $142.9 $12.1 Million - $24.9 Million	-174,010 Reduced 84.91%	30,923 $2.28 Million
Q4 2021 Feb 14, 2022	BUY	$134.56 - $217.97 $18.9 Million - $30.6 Million	140,213 Added 216.65%	204,933 $29.3 Million
Q3 2021 Nov 15, 2021	SELL	$177.8 - $270.58 $4.18 Million - $6.36 Million	-23,492 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$177.8 - $270.58 $11.5 Million - $17.5 Million	64,720 New	64,720 $13.4 Million
Q2 2021 Aug 16, 2021	BUY	$121.0 - $257.67 $2.84 Million - $6.05 Million	23,492 New	23,492 $4.99 Million
Q1 2021 May 14, 2021	SELL	$112.98 - $319.93 $103,037 - $291,776	-912 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$112.98 - $319.93 $8.28 Million - $23.5 Million	-73,305 Reduced 98.77%	912 $165,000
Q4 2020 Feb 16, 2021	BUY	$78.74 - $139.5 $5.84 Million - $10.4 Million	74,217 New	74,217 $8.28 Million
Q4 2020 Feb 16, 2021	SELL	$78.74 - $139.5 $274,723 - $486,715	-3,489 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$79.44 - $178.51 $620,108 - $1.39 Million	-7,806 Reduced 69.11%	3,489 $378,000
Q3 2019 Nov 14, 2019	BUY	$4.02 - $7.84 $45,405 - $88,552	11,295 New	11,295 $56,000

Others Institutions Holding NVAX

# of Institutions

290

Shares Held

93.4M

Call Options Held

6.95M

Put Options Held

9.4M

View Full List

About NOVAVAX INC

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $666M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

More about NVAX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.

Account